Alphabet's AI drug discovery spinoff Isomorphic Labs closed a $2.1 billion Series B on May 12, one of the largest private rounds ever raised in the sector. The round was led by Thrive Capital, with participation from Alphabet, GV, CapitalG, MGX, Temasek and the UK Sovereign AI Fund, bringing the company's total capital base to roughly $2.6 billion.

Founded in 2021 as a DeepMind spinout, Isomorphic Labs will use the cash to scale its proprietary AI drug design engine, IsoDDE, and push its internal pipeline toward the clinic. The company already runs paid discovery partnerships with Novartis, Eli Lilly and Johnson & Johnson covering multiple therapeutic areas.

The deal lands as biotech investors pour record sums into AI-native drug design, betting that models descended from AlphaFold can compress the typical decade-long discovery timeline. Thrive Capital is doubling down after leading the prior round, signaling continued confidence as Isomorphic moves from research platform to clinical-stage company.